A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 2, 2004, Pages 456-464

  Lortholary, Olivier ^a   Charlemagne, Agnès ^b   Bastides, Frédéric ^c   Chevalier, Patrick ^d   Datry, Annick ^e   Gonzalves, Marie France ^f   Michel, Gérard ^g   Tilleul, Patrick ^h   Veber, Benoît ⁱ   Herbrecht, Raoul ^j   Boasson, M ^k   Peny, A M ^l   Demeocq F ^m   Paillard, C ^m   Sotto, J J ⁿ   Garban, F ⁿ   Stahl, J P ⁿ   Contamin, C ⁿ   Bordessoule, D ^o   Turlure, P ^o   Peyramond, D ^p   Fiere D ^q   Thiebaut A ^q   Bastien, O ^r   Ciffier, B ^s   Espinousse, D ^s   Lepape, A ^s   Michel, G ^g   Fuentes P ^t   Reynaud Gaubert, M ^t   Reynes, J ^u   Rieu, D ^v   Montoya, F ^v   Rossi, J F ^v   Milpied, N ^w   Moreau, P ^w   Cassuto, J P ^x   Rosenthal, E ^x   Dellamonica, P ^x   Chaillau, S ^x   Fuzibet, J G ^x   Lescaut, W ^x   Carbon, C ^y   Jolly, V ^y   Fischer, A ^a   Dupuis, S ^a   Hubert, P ^a   Varet, B ^a   Arnulf, B ^a   Bricaire, F ^e   Bossi, P ^e   Vernant, J P ^e   Dhedin, N ^e   Vilmer, E ^z   Larchee R ^z   Najman, A ^h   Isnard Grivaud, F ^h   Baruchel, A ^aa   Reguerre, Y ^aa   Degos, L ^aa   Dombret, H ^aa   Gluckman, E ^aa   Ribaud, P ^aa   Huchon, G ^ab   Rabbat, A ^ab   Marie, J P ^ab   Vekhoff, A ^ab   Camus, C ^ac   Le Prise P Y ^ac   Tilly, H ^ad   Stamatoulas, A ^ad   Caron, F ^ae   Debab, Y ^ae   Giraud, J L ^ae   Vannier, J P ^ae   Veber, B ^ae   Gillet, R ^ae   Lucht, F ^af   Fresard A ^af   Dufour, P ^j   Durand, D ^ag   Bordes, G ^ag   Massip, P ^ag   Bonnet, E ^ag   Pris, J ^ag   Huguet, F ^ag   Canton, P ^ah   Rabaud, C ^ah   Gerard A ^ah   Lederlin P ^ah   Witz, B ^ah   more..

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CEMKA EVAL   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f Hôpital de Ravenel   (France)

^g TIMONE HOSPITAL   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ ROUEN UNIVERSITY HOSPITAL   (France)

^j HÔPITAL DE HAUTEPIERRE   (France)

^k ANGERS UNIVERSITY HOSPITAL   (France)

^l CENTRE FRANÇOIS BACLESSE   (France)

^m HÔTEL DIEU   (France)

ⁿ HÔPITAL MICHALLON   (France)

^o DUPUYTREN UNIVERSITY HOSPITAL   (France)

^p CROIX ROUSSE HOSPITAL   (France)

^q EDOUARD HERRIOT HOSPITAL   (France)

^r LOUIS PRADEL HOSPITAL   (France)

^s CENTRE HOSPITALIER LYON SUD   (France)

^t HÔPITAL SAINTE MARGUERITE   (France)

^u HÔPITAL SAINT ELOI   (France)

^v LAPEYRONIE HOSPITAL   (France)

^w HÔTEL DIEU   (France)

^x CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^y BICHAT HOSPITAL   (France)

^z HÔPITAL ROBERT DEBRÉ   (France)

^aa SAINT LOUIS HOSPITAL   (France)

^ab HÔTEL DIEU   (France)

^ac Hôpital de Pontchaillou   (France)

^ad CENTRE HENRI BECQUEREL   (France)

^ae HÔPITAL CHARLES NICOLLE   (France)

^af SERVICE DE NEUROLOGIE   (France)

^ag CHU PURPAN   (France)

^ah UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

Aspergillosis; Candidiasis; Cryptococcosis; Pharmacoepidemiology

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFUNGAL AGENT; CASPOFUNGIN; CONTRAST MEDIUM; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSCARNET; IFOSFAMIDE; INDINAVIR; INTERLEUKIN 2; IODINE; ITRACONAZOLE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 3; PENTAMIDINE; PLATINUM DERIVATIVE; PYRROLE DERIVATIVE; RITONAVIR; SULFADIAZINE; SULFAMETHOXAZOLE; TACROLIMUS; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; CRYPTOCOCCOSIS; DISEASE ASSOCIATION; DRUG FATALITY; FEMALE; FRANCE; HEMATOLOGIC MALIGNANCY; HEMATOLOGY; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MULTIVARIATE ANALYSIS; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PROBABILITY; RETROSPECTIVE STUDY; RISK FACTOR; SURGERY; TREATMENT OUTCOME;

EID: 4444259152     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh348     Document Type: Article

References (40)

1. Beck-Sague, C. & Jarvis, W. R. (1993). Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. Journal of Infectious Diseases 167, 1247-51.
2. Vincent, J. L., Bihari, D. J., Suter, P. M. et al. (1995). The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. Journal of the American Medical Association 274, 634-44.
3. Valles, J., Leon, C. & Alvarez-Lerma, F. (1997). Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Spanish collaborative group for infections in intensive care unit of Sociedad Espanola de Medicina Intensiva Unidades Coronarias (SEMIUC). Clinical Infectious Diseases 24, 387-95.
4. Edmond, M. B., Wallace, S. E., McClish, D. K. et al. (1999). Nosocomial bloodstream infections in United States hospitals three-year analysis. Clinical Infectious Diseases 29, 239-44.
5. Lamagni, T. L., Evans, B. G., Shigematsu, M. et al. (2001). Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9). Epidemiology and Infection 126, 397-414.
6. Marr, K. A., Carter, R. A., Crippa, F. et al. (2002). Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clinical Infectious Diseases 34, 909-17.
7. McNeil, M. M., Nash, S. L., Hajjeh, R. A. et al. (2001). Trends in mortality due to intensive mycotic diseases in the United States, 1980-1997. Clinical Infectious Diseases 33, 641-7.
8. Lin, S. J., Schranz, J. & Teutsch, S. M. (2001). Aspergillosis case-fatality rate: systemic review of the literature. Clinical Infectious Diseases 32, 358-66.
9. Blumberg, H. M., Jarvis, W. R., Soucie, J. M. et al. (2001). Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clinical Infectious Diseases 33, 177-86.
10. Petri, M. G., König, J., Moecke, H. P. et al. (1997). Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Medicine 23, 317-25.
11. Lortholary, O., Droz, C., Sitbon, K. et al. (2003). Long-term outcome of HIV-associated cryptococcosis (CC) at the time of HAART. Results of the multicenter cohort "Cryptostop". In Programs and Abstracts of the Forty-third Interscience, Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract M-1752, p. 475. American Society for Microbiology, Washington, DC, USA.
12. Martino, R. & Subira, M. (2002). Invasive fungal infections in hematology: new trends. Annals of Hematology 81, 233-43.
13. Fisher-Hoch, S. P. & Hutwagner, L. (1995). Opportunistic candidiasis: an epidemic of the 1980s. Clinical Infectious Diseases 21, 897-904.
14. Fridkin, S. K. & Jarvis, W. R. (1996). Epidemiology of nosocomial fungal infections. Clinical Microbiology Reviews 9, 499-511.
15. Ellis, M., Richardson, M. & de Pauw, B. (2000). Epidemiology. Hospital Medicine 61, 605-9.
16. Masia Canuto, M. & Gutierrez Rodero, F. (2002). Antifungal drug resistance to azoles and polyenes. Lancet Infectious Diseases 2, 550-63.
17. Denning, D. W., Venkateswarlu, K., Oakley, K. L. et al. (1997). Itraconazole resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy 41, 1364-8.
18. Dannaoui, E., Borel, E., Monier, M. F. et al. (2001). Acquired itraconazole resistance in Aspergillus fumigatus. Journal of Antimicrobial Chemotherapy 47, 333-40.
19. Alexander, B. D. (2002). Diagnosis of fungal infection: new technologies for the mycology laboratory. Transplant Infectious Disease 4, Suppl. 3, 32-7.
20. Guillemot, D. (2001). How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach. Clinical Microbiology and Infection 7, Suppl. 5, 19-23.
21. Cockcroft, D. W. & Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41.
22. Ascioglu, S., Rex, J. H., de Pauw, B. et al. (2002). Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clinical Infectious Diseases 34, 7-14.
23. Manuel, R. J. & Kibbler, C. C. (1998). The epidemiology and prevention of invasive aspergillosis. Journal of Hospital Infection 39, 95-109.
24. Patterson, T. F., Kirkpatrick, W. R., White, M. et al. (2000). Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine 79, 250-60.
25. Dromer, F., Mathoulin-Pelissier, S., Fontanet, A. et al. (2004). Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS 18, 555-62.
26. Viscoli, C. & Castagnola, E. (1998-99). Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review. International Journal of Infectious Diseases 3, 109-18.
27. De Marie, S. (2000). New developments in the diagnosis and management of invasive fungal infections. Haematologica 85, 88-93.
28. Pfaller, M. A. (2000). Epidemiology of nosocomial candidiasis: the importance of molecular typing. Brazilian Journal of Infectious Diseases 4, 161-7.
29. Rangel-Frausto, M. S., Wiblin, T., Blumberg, H. M. et al. (1999). National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida Species in seven surgical intensive care units and six neonatal intensive care units. Clinical Infectious Diseases 29, 253-8.
30. Richet, H., Roux, P., Des Champs, C. et al. (2002). Candidemia in French hospitals: Incidence rates and characteristics. Clinical Microbiology and Infection 8, 405-12.
31. Denning, D. W. & Stevens, D. A. (1990). Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Reviews in Infectious Diseases 12, 1147-201.
32. Schöffski, P., Freund, M., Wunder, R. et al. (1998). Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. British Medical Journal 317, 379-84.
33. Heide, P. E. (1997). Precipitation of amphotericin B from i.v. fat emulsion. American Journal of Health-System Pharmacy 54, 1449.
34. Herbrecht, R., Denning, D. W., Patterson, T. F. et al. (2002). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine 347, 408-15.
35. Wey, S. B., Mori, M., Pfaller, M. A. et al. (1988). Hospital-acquired candidemia. The attributable mortality and excess length of stay. Archive of Internal Medicine 148, 2642-5.
36. Rex, J. H., Bennett, J. E., Sugar, A. M. et al. (1994). A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New England Journal of Medicine 331, 1326-30.
37. Pfaller, M. & Wenzel, R. (1992). Impact of the changing epidemiology of fungal infections in the 1990s. European Journal of Clinical Microbiology and Infectious Diseases 11, 287-91.
38. Anaissie, E. J., Rex, J. H., Uzun, O. et al. (1998). Predictors of adverse outcome in cancer patients with candidemia. American Journal of Medicine 104, 238-45.
39. Bates, D. W., Su, L., Yu, D. T. et al. (2001). Mortality and costs of acute renal failure associated with amphotericin B therapy. Clinical Infectious Diseases 32, 686-93.
40. Wingard, J. R. (1994). Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clinical Infectious Diseases 19, Suppl. 1, S49-53.